Please assess the completion status of the following clinical trial:

Trial Title: Acetazolamide and Spironolactone to Increase Natriuresis in Congestive Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Older than 18 years and able to give informed consent~* Clinical diagnosis of acute decompensated heart failure within the previous 8 h~* At least two clinical signs of congestion (edema, ascites, jugular venous distension, or pulmonary vascular congestion on chest radiography)~* Maintenance therapy with oral loop diuretics at a dose of at least 1 mg bumetanide (1 mg bumetanide = 40 mg furosemide = 20 mg torsemide) for at least 1 month before hospital admission~* NT-proBNP \>1000 ng/L~* Left ventricular ejection fraction \<50%~* At least one out of three of the following criteria:~  * Serum sodium \<136 mmol/L~ * Serum urea/creatinine ratio \>50 (comparable to a BUN/creatinine ratio \>25)~ * Admission serum creatinine increased with \>0.3 mg/dL compared to previous value within 3 months before admission~Exclusion Criteria:~* History of cardiac transplantation and/or ventricular assist device~* Concurrent diagnosis of an acute coronary syndrome defined as typical chest pain and/or electrocardiographic changes in addition to a troponin rise \>99th percentile~* Mean arterial blood pressure \<65 mmHg, or systolic blood pressure \<90 mmHg at the moment of admission~* Use of intravenous inotropes, vasopressors or nitroprusside at any time point during the study~* A baseline estimated glomerular filtration rate \<15 mL/min/1.73m² according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula at the moment of inclusion~* Use of renal replacement therapy or ultrafiltration before study inclusion~* Treatment with acetazolamide within the previous month~* Treatment with ≥2 mg bumetanide or an equivalent dose during the index hospitalization before randomization~* Use of diuretics, vasopressin antagonists or mineralocorticoid receptor antagonist not specified by the protocol~* Exposure to nephrotoxic agents (i.e. contrast dye) anticipated within 3 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Acetazolamide/low-dose loop diuretics, upfront spironolactone (Type: EXPERIMENTAL): 2x2 factorial design: This group is the experimental group for both study interventions (acetazolamide and upfront spironolactone).~See interventions for more details.
- High-dose loop diuretics, upfront spironolactone (Type: EXPERIMENTAL): 2x2 factorial design: This group is the experimental group for the study intervention with upfront spironolactone. This group receives high-dose loop diuretics as an active comparator to the study intervention with acetazolamide.~See interventions for more details.
- Acetazolamide/low-dose loop diuretics, no spironolactone (Type: EXPERIMENTAL): 2x2 factorial design: This group is the experimental group for the study intervention with acetazolamide. This group receives no intervention with regards to the spironolactone arm.~See interventions for more details.
- High-dose loop diuretics, no spironolactone (Type: ACTIVE_COMPARATOR): 2x2 factorial design: This group receives high-dose loop diuretics as an active comparator to the study intervention with acetazolamide. This group receives no intervention with regards to the spironolactone arm.~See interventions for more details.

Based on this trial design, predict the completion outcome and termination type (if applicable).